论文部分内容阅读
目的探讨血清甲胎蛋白(AFP)和细胞角质蛋白19片段(CYFRA21-1)对原发性肝癌诊断的临床价值。方法采用化学发光法测定51例原发性肝癌患者、32例肝良性疾病患者血清AFP和CYFRA21-1水平,并与40例正常对照组比较。结果原发性肝癌组患者血清AFP和CYFRA21-1水平[(498.29±192.08)ng/ml和(5.01±3.27)ng/ml]明显高于肝良性病组[(81.63±11.25)ng/ml和(2.14±1.76)ng/ml]和正常对照组[(83.90±19.78)ng/ml和(1.83±1.18)ng/ml](P<0.01)。以血清AFP和CYFRA21-1水平为指标检测原发性肝癌的敏感性分别为65.8%和95.7%,特异性分别为69.9%和80.1%,两项联合检测的敏感性和特异性则分别提高至为90.5%和83.6%。结论联合检测血清中的AFP与CYFRA21-1对原发性肝癌的诊断具有重要价值。
Objective To investigate the clinical value of serum alpha-fetoprotein (AFP) and cytokeratin 19 (CYFRA21-1) in the diagnosis of primary liver cancer. Methods The levels of serum AFP and CYFRA21-1 in 51 patients with primary liver cancer and 32 patients with benign liver diseases were measured by chemiluminescence method and compared with 40 normal controls. Results The levels of serum AFP and CYFRA21-1 in patients with primary liver cancer [(498.29 ± 192.08) ng / ml and (5.01 ± 3.27) ng / ml] were significantly higher than those in benign liver disease group [(81.63 ± 11.25) ng / ml and (2.14 ± 1.76) ng / ml] and normal control group [(83.90 ± 19.78) ng / ml and (1.83 ± 1.18) ng / ml], respectively. The sensitivity and specificity of detection of serum AFP and CYFRA21-1 were 65.8% and 95.7%, respectively, the specificity was 69.9% and 80.1% respectively. The sensitivity and specificity of the two combined tests were increased to 90.5% and 83.6%. Conclusion Combined detection of serum AFP and CYFRA21-1 in the diagnosis of primary liver cancer is of great value.